WO2003020313A1 - Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate - Google Patents

Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate Download PDF

Info

Publication number
WO2003020313A1
WO2003020313A1 PCT/JP2002/008926 JP0208926W WO03020313A1 WO 2003020313 A1 WO2003020313 A1 WO 2003020313A1 JP 0208926 W JP0208926 W JP 0208926W WO 03020313 A1 WO03020313 A1 WO 03020313A1
Authority
WO
WIPO (PCT)
Prior art keywords
sphingosine
remedies
respiratory diseases
phosphate receptor
controller
Prior art date
Application number
PCT/JP2002/008926
Other languages
English (en)
French (fr)
Inventor
Shinji Nakade
Hidehiro Suzuki
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Priority to US10/488,546 priority Critical patent/US20040235794A1/en
Priority to EP02772831A priority patent/EP1424078A4/en
Priority to JP2003524620A priority patent/JPWO2003020313A1/ja
Publication of WO2003020313A1 publication Critical patent/WO2003020313A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
PCT/JP2002/008926 2001-09-04 2002-09-03 Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate WO2003020313A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/488,546 US20040235794A1 (en) 2001-09-04 2002-09-03 Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
EP02772831A EP1424078A4 (en) 2001-09-04 2002-09-03 RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
JP2003524620A JPWO2003020313A1 (ja) 2001-09-04 2002-09-03 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001266595 2001-09-04
JP2001-266595 2001-09-04

Publications (1)

Publication Number Publication Date
WO2003020313A1 true WO2003020313A1 (fr) 2003-03-13

Family

ID=19092856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008926 WO2003020313A1 (fr) 2001-09-04 2002-09-03 Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate

Country Status (4)

Country Link
US (1) US20040235794A1 (ja)
EP (1) EP1424078A4 (ja)
JP (1) JPWO2003020313A1 (ja)
WO (1) WO2003020313A1 (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010987A2 (en) * 2002-07-24 2004-02-05 Novartis Ag Use of s1p receptor agonists in heart diseases
WO2004074297A1 (ja) 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
JP2006528987A (ja) * 2003-05-19 2006-12-28 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
WO2008018427A1 (fr) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
JP2009137969A (ja) * 2004-12-13 2009-06-25 Ono Pharmaceut Co Ltd アミノカルボン酸誘導体およびその医薬用途
WO2011004604A1 (ja) 2009-07-09 2011-01-13 杏林製薬株式会社 ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬
WO2012086184A1 (ja) 2010-12-21 2012-06-28 杏林製薬株式会社 ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬
JP2013506003A (ja) * 2009-09-29 2013-02-21 アラーガン インコーポレイテッド スフィンゴシン−１−リン酸−２（ｓ１ｐ２）受容体のサブタイプ選択的調節因子としての縮合環ピリジン化合物
CN106232182A (zh) * 2013-12-02 2016-12-14 梯瓦制药工业有限公司 S1p3拮抗剂

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050121712A (ko) 2003-04-08 2005-12-27 노파르티스 아게 유기 화합물
PL1772145T3 (pl) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym
US7795472B2 (en) * 2004-10-12 2010-09-14 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
DK1932522T3 (da) * 2005-10-07 2012-07-02 Kyorin Seiyaku Kk Terapeutisk middel mod leversygdom indeholdende 2-amino-1,3-propandiolderivat som aktiv bestanddel
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EA200802058A1 (ru) * 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
CN101506145B (zh) * 2006-08-08 2013-05-29 杏林制药株式会社 氨基醇衍生物以及将它们作为有效成分的免疫抑制剂
MX2020001259A (es) * 2006-09-26 2020-03-20 Novartis Ag Composiciones farmaceuticas que comprenden un modulador de s1p.
WO2008154470A1 (en) * 2007-06-08 2008-12-18 University Of Connecticut Nhibitor of the receptor activity of the s1p2 receptor for inhibiting pathological angiogenesis in the eye
TW200946105A (en) * 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
EP2831072B1 (en) * 2012-03-26 2017-04-19 Arroyo BioSciences L.L.C. Novel sphingosine 1-phosphate receptor antagonists
EP3148550B1 (en) 2014-06-02 2020-10-28 Dalhousie University Treatment of familial exudative vitreoretinopathy through s1pr2 inhibition
CA2987796A1 (en) * 2015-06-01 2016-12-08 Dalhousie University S1pr2 antagonists and uses therefor
US10487082B2 (en) 2015-06-01 2019-11-26 Dalhousie University S1PR2 antagonists and uses therefor
US10858358B2 (en) 2015-06-01 2020-12-08 Dalhousie University S1PR2 antagonists and uses therefor
CA2993621A1 (en) * 2015-08-11 2017-02-16 Akaal Pharma Pty Ltd Compositions comprising s1p receptor modulators
EP3706728A1 (en) * 2017-11-08 2020-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) S1pr2 antagonists for treating diseases involving abnormal immune responses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
WO2001098301A1 (fr) * 2000-06-20 2001-12-27 Japan Tobacco Inc. Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments
JP2002212070A (ja) * 2001-01-24 2002-07-31 Ono Pharmaceut Co Ltd アスパラギン酸誘導体を有効成分として含有するスフィンゴシン−１−リン酸拮抗剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154024B (it) * 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
WO1989003385A1 (en) * 1987-10-13 1989-04-20 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
JPH08198876A (ja) * 1995-01-30 1996-08-06 Yoshitomi Pharmaceut Ind Ltd トランス−Ｎ−（１Ｈ−ピラゾロ〔３，４−ｂ〕ピリジン−４−イル）−４−グアニジノメチルシクロヘキサンカルボキサミド・１メタンスルホン酸塩・１水和物
KR20000035869A (ko) * 1996-08-30 2000-06-26 가마쿠라 아키오 근조직 변성의 예방 또는 치료제
US6057126A (en) * 1997-12-24 2000-05-02 Allelix Biopharmaceuticals, Inc. Mammalian EDG-5 receptor homologs
US6423508B1 (en) * 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
US20010038825A1 (en) * 2000-02-04 2001-11-08 Hite Robert Duncan Method and compositions for enhancing pulmonary function and treating pulmonary disorders
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
CA2432978C (en) * 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
DE60234092D1 (de) * 2001-01-30 2009-12-03 Univ Virginia Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren
PL365443A1 (en) * 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
US7220764B2 (en) * 2002-06-17 2007-05-22 The Pennsylvania State University Research Foundation Sphingosine kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
WO2001098301A1 (fr) * 2000-06-20 2001-12-27 Japan Tobacco Inc. Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments
JP2002212070A (ja) * 2001-01-24 2002-07-31 Ono Pharmaceut Co Ltd アスパラギン酸誘導体を有効成分として含有するスフィンゴシン−１−リン酸拮抗剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMMIT ALAINA J. ET AL.: "Shingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma", THE FASEB JOURNAL, vol. 15, no. 7, May 2001 (2001-05-01), pages 1212 - 1214, XP002961011 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910626B2 (en) 2002-07-24 2011-03-22 Novartis Ag Use of S1P receptor agonists in heart diseases
WO2004010987A3 (en) * 2002-07-24 2004-04-15 Novartis Ag Use of s1p receptor agonists in heart diseases
WO2004010987A2 (en) * 2002-07-24 2004-02-05 Novartis Ag Use of s1p receptor agonists in heart diseases
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
US7763752B2 (en) 2002-09-19 2010-07-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivatives, salts thereof and immunosuppresive agents
WO2004074297A1 (ja) 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
US7456157B2 (en) 2003-02-18 2008-11-25 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
US7759326B2 (en) 2003-02-18 2010-07-20 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivative, salt thereof, and modulator of S1P receptor
JP2006528987A (ja) * 2003-05-19 2006-12-28 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
JP2009137969A (ja) * 2004-12-13 2009-06-25 Ono Pharmaceut Co Ltd アミノカルボン酸誘導体およびその医薬用途
WO2008018427A1 (fr) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif
WO2011004604A1 (ja) 2009-07-09 2011-01-13 杏林製薬株式会社 ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬
JP2013506003A (ja) * 2009-09-29 2013-02-21 アラーガン インコーポレイテッド スフィンゴシン−１−リン酸−２（ｓ１ｐ２）受容体のサブタイプ選択的調節因子としての縮合環ピリジン化合物
WO2012086184A1 (ja) 2010-12-21 2012-06-28 杏林製薬株式会社 ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬
US8993543B2 (en) 2010-12-21 2015-03-31 Kyorin Pharmaceutical Co., Ltd. Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient
CN106232182A (zh) * 2013-12-02 2016-12-14 梯瓦制药工业有限公司 S1p3拮抗剂
CN106232182B (zh) * 2013-12-02 2019-11-01 梯瓦制药工业有限公司 S1p3拮抗剂

Also Published As

Publication number Publication date
JPWO2003020313A1 (ja) 2004-12-16
EP1424078A1 (en) 2004-06-02
US20040235794A1 (en) 2004-11-25
EP1424078A4 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
WO2003020313A1 (fr) Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
CY1108326T1 (el) ΝΕΟΣ ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ ΚΑΙ β ΜΙΜΗΤΙΚΩΝ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΑΝΑΠΝΕΥΣΤΙΚΩΝ ΑΣΘΕΝΕΙΩΝ
EP3494995A3 (en) Formoterol superfine formulation
WO2002032410A3 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
CN106413789A (zh) 用于呼吸治疗装置的湿化器
WO2005058867A8 (en) Benzothiophene-and thiochromene containing phenethanolamine derivatives for the treatment of respiratory disorders
WO2006018718A3 (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
WO2006033963A3 (en) Method and system of scoring sleep disordered breathing
WO2005115241A3 (en) Method and system for diagnosing central versus obstructive apnea
WO2008112353A3 (en) Instrumented metered-dose inhaler and methods for predicting disease exacerbations
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
ATE466591T1 (de) Interferon-beta zur antiviralen therapie für atemwegserkrankungen
NO20075287L (no) Kombinasjon av antikolinergika og leukotnen-reseptorantagonister for behandling av andedrettslidelser
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
WO2003079992A3 (en) Pulmonary delivery for levodopa
WO2006012640A3 (en) Method of administration of dopamine receptor agonists
EP1513509A4 (en) DEHYDROEPIANDROSTERONE FORMULATIONS FOR NEBULIZING AND METHODS FOR TREATING ASTRONIC OR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING THE CORRESPONDING COMPOSITIONS
Regli et al. Anesthesia and ventilation strategies in children with asthma: part II–intraoperative management
Lin et al. Aerosol delivery via invasive ventilation: a narrative review
EP1448185A4 (en) TREATMENT OF ASTHMA, CHRONIC OBSTRUCTIVE LUNG DISEASES AND / OR OTHER RESPIRATORY PROBLEMS
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
Kárason et al. Ventilator treatment in the Nordic countries. A multicenter survey
RS20060292A (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
TW200610529A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003524620

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002772831

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10488546

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002772831

Country of ref document: EP